Viatris Inc. VTRS
17.83
0.41
2.35%
as of 25 Sep
- Market cap
- $20.0B
- P/E
- 0.0×
Follow VTRS
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years
Viatris Inc. (VTRS) Net margin
Viatris Inc.'s net margin over the twelve months to 30 June 2026 was −2.79%, up 21.8 percentage points from fiscal 2025 (−24.6%). Over the past ten years it has ranged from −24.6% (fiscal 2025) to 12.8% (fiscal 2022) — the current reading is the lowest in ten years. That is below the Drug Manufacturers Specialty & Generic industry median of 0.00% and below the Healthcare sector median of 0.00%.
Net margin, annual
Annual
| Period | Net margin | Change (points) |
|---|---|---|
| FY2025 | −24.6% | (20.28) |
| FY2024 | −4.30% | (4.65) |
| FY2023 | 0.35% | (12.43) |
| FY2022 | 12.8% | 19.88 |
| FY2021 | −7.10% | (1.49) |
| FY2020 | −5.61% | (5.76) |
| FY2019 | 0.15% | (2.93) |
| FY2018 | 3.08% | (2.76) |
| FY2017 | 5.84% | 1.51 |
| FY2016 | 4.33% | (4.66) |
Quarterly
| Period | Net margin | Change (points) |
|---|---|---|
| Jun 2026 | −3.16% | (8.18) |
| Mar 2026 | 5.02% | 14.20 |
| Dec 2025 | −9.18% | (5.77) |
| Sep 2025 | −3.41% | (3.28) |
| 42 more quarters | Free account |
Against its own ten years
Low −24.6%
High 12.8%
Ten-year median
0.35%
Current reading's percentile
9
Net margin against peers
| Company | Net margin |
|---|---|
| UTHR United Therapeutics Corporation compare | 41.6% |
| ZTS Zoetis Inc. compare | 27.7% |
| NBIX Neurocrine Biosciences, Inc. compare | 20.9% |
| HLN Haleon PLC Sponsored ADR compare | 13.8% |
| RDY Dr. Reddy's Laboratories Ltd compare | 9.81% |
| TEVA Teva Pharmaceutical Industries Ltd. compare | 4.08% |
| VTRS Viatris Inc. | −2.79% |
| ELAN Elanco Animal Health Incorporated compare | −3.96% |
| HIMS Hims & Hers Health, Inc. compare | −5.51% |
| Drug Manufacturers Specialty & Generic industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.55% |
What Net margin is
Net Profit Margin tells an investor how much of each unit of revenue ends up as profit for shareholders after all costs, interest and taxes.
Net Income Allotted to Shareholders ÷ Revenue
More on VTRS
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement